Enspryng Interactions
There are 343 drugs known to interact with Enspryng (satralizumab), along with 3 disease interactions. Of the total drug interactions, 59 are major, 277 are moderate, and 7 are minor.
- View all 343 medications that may interact with Enspryng
- View Enspryng disease interactions (3)
Most frequently checked interactions
View interaction reports for Enspryng (satralizumab) and the medicines listed below.
- acetaminophen / hydrocodone
- Acidophilus Probiotic Blend (lactobacillus acidophilus)
- Adderall XR (amphetamine / dextroamphetamine)
- Advate (antihemophilic factor)
- Afinitor (everolimus)
- Afrin (oxymetazoline nasal)
- Afstyla (antihemophilic factor)
- Aimovig (erenumab)
- Ajovy (fremanezumab)
- AK-Sulf (sulfacetamide sodium ophthalmic)
- Aleve (naproxen)
- Allegra (fexofenadine)
- alprazolam
- aluminum hydroxide / magnesium trisilicate
- amoxapine
- amoxicillin
- amphetamine / dextroamphetamine
- Ampyra (dalfampridine)
- Aralen (chloroquine)
- armodafinil
- ashwaganda
- Astelin (azelastine nasal)
- Atromid-S (clofibrate)
- Aubagio (teriflunomide)
- Augmentin (amoxicillin / clavulanate)
- Celebrex (celecoxib)
- duloxetine
- gabapentin
- prednisone
- tramadol
Enspryng disease interactions
There are 3 disease interactions with Enspryng (satralizumab) which include:
Report options
QR code containing a link to this page
More about Enspryng (satralizumab)
- Enspryng consumer information
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: interleukin inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.